EA202190699A1 - Альтернативные способы получения тубулизинов и их промежуточных соединений - Google Patents

Альтернативные способы получения тубулизинов и их промежуточных соединений

Info

Publication number
EA202190699A1
EA202190699A1 EA202190699A EA202190699A EA202190699A1 EA 202190699 A1 EA202190699 A1 EA 202190699A1 EA 202190699 A EA202190699 A EA 202190699A EA 202190699 A EA202190699 A EA 202190699A EA 202190699 A1 EA202190699 A1 EA 202190699A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tubulisins
obtaining
alternative methods
intermediate compounds
compounds
Prior art date
Application number
EA202190699A
Other languages
English (en)
Russian (ru)
Inventor
Кунь-Лян У
Цинву Цзинь
Вендел Даблдэй
Original Assignee
Сиджен Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сиджен Инк. filed Critical Сиджен Инк.
Publication of EA202190699A1 publication Critical patent/EA202190699A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EA202190699A 2018-09-07 2019-09-06 Альтернативные способы получения тубулизинов и их промежуточных соединений EA202190699A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862728639P 2018-09-07 2018-09-07
PCT/US2019/050023 WO2020051503A1 (en) 2018-09-07 2019-09-06 Alternative processes for the preparation of tubulysins and intermediates thereof

Publications (1)

Publication Number Publication Date
EA202190699A1 true EA202190699A1 (ru) 2021-06-08

Family

ID=68000124

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190699A EA202190699A1 (ru) 2018-09-07 2019-09-06 Альтернативные способы получения тубулизинов и их промежуточных соединений

Country Status (17)

Country Link
US (1) US20230002440A1 (enExample)
EP (1) EP3847161A1 (enExample)
JP (1) JP7511543B2 (enExample)
KR (1) KR20210073525A (enExample)
CN (1) CN112996778A (enExample)
AU (1) AU2019336231A1 (enExample)
BR (1) BR112021004317A2 (enExample)
CA (1) CA3111149A1 (enExample)
EA (1) EA202190699A1 (enExample)
IL (1) IL281090A (enExample)
MA (1) MA53550A (enExample)
MX (1) MX2021002570A (enExample)
SA (1) SA521421375B1 (enExample)
SG (1) SG11202102126VA (enExample)
TW (1) TWI825169B (enExample)
UA (1) UA128730C2 (enExample)
WO (1) WO2020051503A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020482800B2 (en) * 2020-12-23 2025-08-21 Genequantum Healthcare (Suzhou) Co., Ltd. Novel isomeric compounds comprising a ring-opened thiosuccinimide group, an oligopeptide fragment and a chiral moiety
JP2024510435A (ja) 2021-03-18 2024-03-07 シージェン インコーポレイテッド 生体活性化合物の内部移行複合体からの選択的薬物放出

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2148886B1 (en) * 2007-05-10 2014-02-19 R & D Biopharmaceuticals Gmbh Tubulysine derivatives
IT1394860B1 (it) 2009-07-22 2012-07-20 Kemotech S R L Composti farmaceutici
US11229708B2 (en) 2015-12-04 2022-01-25 Seagen Inc. Conjugates of quaternized tubulysin compounds
MA50124A (fr) * 2017-09-08 2020-07-15 Seattle Genetics Inc Procédé de préparation de tubulysines et d'intermédiaires de celles-ci

Also Published As

Publication number Publication date
SA521421375B1 (ar) 2024-02-11
EP3847161A1 (en) 2021-07-14
MA53550A (fr) 2021-12-15
CN112996778A (zh) 2021-06-18
JP7511543B2 (ja) 2024-07-05
TWI825169B (zh) 2023-12-11
WO2020051503A1 (en) 2020-03-12
KR20210073525A (ko) 2021-06-18
CA3111149A1 (en) 2020-03-12
US20230002440A1 (en) 2023-01-05
AU2019336231A1 (en) 2021-03-18
TW202024043A (zh) 2020-07-01
BR112021004317A2 (pt) 2021-05-25
JP2021536475A (ja) 2021-12-27
SG11202102126VA (en) 2021-04-29
IL281090A (en) 2021-04-29
UA128730C2 (uk) 2024-10-09
MX2021002570A (es) 2021-06-08

Similar Documents

Publication Publication Date Title
EA201891202A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891201A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890050A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890049A1 (ru) Композиции, содержащие бактериальные штаммы
EA201691541A1 (ru) Новые анти-baff антитела
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
JOP20220119A1 (ar) أجسام مضادة trem2 واستخداماتها
MX390083B (es) Formulaciones de (r)-2-amino-3-fenilpropil carbamato.
MX2018015280A (es) Conjugados de anticuerpo y farmaco anti-egfr.
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
EA201892430A1 (ru) Синтез индазолов
EA202091259A1 (ru) Способ получения опикапона и его интермедиатов
PH12019501359A1 (en) Polymorphs
EA201890572A1 (ru) Биофармацевтические композиции
EA202190810A1 (ru) Способы и наборы для получения цельной крови с инактивированным патогеном
EA202091337A1 (ru) Ингибиторы гистонацетилтрансфераз семейства myst
EA201992360A1 (ru) Кристаллические формы (s)-афоксоланера
EA201692034A1 (ru) Новые макроциклические соединения
EA202092849A1 (ru) Моноспецифические и мультиспецифические антитела к tmeff2 и их применение
EA201891299A1 (ru) Терапевтические антитела к cd9
EA201992883A1 (ru) АНТИТЕЛА К TrkB
EA201791391A1 (ru) Способы получения соединения диарилтиогидантоин
EA201790982A1 (ru) Синтез копанлисиба и его дигидрохлорида
EA202091471A1 (ru) Полиморфы
EA201691632A1 (ru) Пиразины в качестве модуляторов gpr6